Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Annovis Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ANVS
New York
8731
https://www.annovisbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Annovis Bio Inc
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet
- Mar 21st, 2024 1:55 pm
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Mar 20th, 2024 11:30 am
Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?
- Mar 18th, 2024 12:52 pm
Sell Signal: 3 Stocks to Unload Before the Bubble Bursts
- Mar 6th, 2024 8:33 pm
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
- Feb 27th, 2024 1:00 pm
12 $10 Stocks That Will Triple
- Feb 26th, 2024 6:14 pm
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Feb 14th, 2024 12:30 pm
3 Growth Stocks to Sell in February Before They Bottom
- Feb 12th, 2024 9:06 pm
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
- Jan 30th, 2024 1:00 pm
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
- Jan 24th, 2024 1:00 pm
Insiders own 28% of Annovis Bio, Inc. (NYSE:ANVS) shares but individual investors control 57% of the company
- Jan 24th, 2024 11:27 am
These Stocks under $10 Are Poised To Explode
- Dec 21st, 2023 9:13 pm
Annovis Bio to Participate in the 139th Yale CEO Summit
- Dec 11th, 2023 6:00 pm
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
- Dec 5th, 2023 12:30 pm
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
- Dec 1st, 2023 4:12 pm
Annovis Bio Appoints Andrew Walsh as Vice President Finance
- Dec 1st, 2023 12:30 pm
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
- Nov 27th, 2023 12:30 pm
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 8th, 2023 10:00 pm
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
- Nov 2nd, 2023 11:30 am
Annovis Bio Announces Pricing of $7.5 Million Public Offering
- Oct 31st, 2023 12:00 pm
Scroll